Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Deseret News Utah Index
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aptose Bioscns
(NQ:
APTO
)
0.6650
UNCHANGED
Streaming Delayed Price
Updated: 3:59 PM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
0.6650
Bid (Size)
0.6500 (5)
Ask (Size)
1.010 (31)
Prev. Close
0.6650
Today's Range
0.6650 - 0.6650
52wk Range
0.6500 - 5.100
Shares Outstanding
93,653,662
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Aptose Announces Results from Annual and Special Meeting of Shareholders
June 18, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
June 14, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Performance
YTD
-72.06%
-72.06%
1 Month
-23.56%
-23.56%
3 Month
-47.22%
-47.22%
6 Month
-69.77%
-69.77%
1 Year
-84.39%
-84.39%
More News
Read More
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
June 03, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Recap: Aptose Biosciences Q4 Earnings
March 26, 2024
Via
Benzinga
Aptose Biosciences's Earnings: A Preview
March 25, 2024
Via
Benzinga
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
May 31, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
APTO Stock Earnings: Aptose Biosciences Beats EPS for Q1 2024
May 14, 2024
Via
InvestorPlace
Aptose Reports Results for the First Quarter 2024
May 14, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Biosciences: Q3 Earnings Insights
November 09, 2023
Via
Benzinga
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024
May 06, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
APTO Stock Earnings: Aptose Biosciences Beats EPS for Q4 2023
March 26, 2024
Via
InvestorPlace
Aptose Reports Results for the Fourth Quarter and Full Year 2023
March 26, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
March 18, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Earnings Scheduled For March 26, 2024
March 26, 2024
Via
Benzinga
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
January 31, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Levi Strauss Layoffs 2024: What to Know About the Latest LEVI Job Cuts
January 26, 2024
Via
InvestorPlace
Topics
Economy
Workforce
Exposures
Economy
Layoff
Why Is SU Group (SUGP) Stock Moving Today?
January 26, 2024
Via
InvestorPlace
Topics
Initial Public Offering
Exposures
Securities Market
Why Is Aptose Biosciences (APTO) Stock Down Today?
January 26, 2024
Via
InvestorPlace
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
January 26, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Why Tellurian Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
January 26, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
January 26, 2024
Via
InvestorPlace
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
December 09, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
November 30, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Reports Results for the Third Quarter 2023
November 09, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
November 02, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.